Product image of Leuprone 1-Monatsdepot (Leuprorelin) supplied by GNH India

Leuprone 1-Monatsdepot

Active Ingredient:
Leuprorelin
Origin:
EU

Leuprone 1-Monatsdepot (Leuprorelin)

Leuprorelin, the active ingredient in Leuprone 1-Monatsdepot, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a 1‑month depot injection for subcutaneous use. It treats hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids, precocious puberty, and hormone‑sensitive breast cancer (off‑label).

GNH India supplies Leuprone 1-Monatsdepot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Leuprone 1-Monatsdepot is a GnRH agonist used in several hormone‑dependent disease areas.

  • Prostate cancer: lowers testosterone levels to inhibit tumor growth.
  • Endometriosis: suppresses estrogen production to reduce lesion activity and pain.
  • Uterine fibroids: decreases ovarian hormone stimulation, leading to fibroid shrinkage.
  • Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis.
  • Hormone‑sensitive breast cancer (off‑label): reduces circulating estrogen to limit tumor progression.

How It Works

  • Leuprorelin is a synthetic GnRH agonist that initially stimulates pituitary GnRH receptors, causing a transient surge in LH and FSH release. Continuous exposure then down‑regulates these receptors, markedly decreasing LH and FSH secretion, which in turn reduces gonadal sex hormone production (testosterone and estrogen). This hormonal suppression underlies its therapeutic effects in hormone‑sensitive conditions.

Side Effects

Leuprone 1-Monatsdepot may cause a range of adverse reactions.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Injection site reactions: pain, redness, or swelling at the subcutaneous site.
  • Headache: mild to moderate intensity.
  • Fatigue: general tiredness or lack of energy.
  • Nausea: occasional upset stomach.
  • Decreased libido: reduced sexual desire.

Serious or Rare Side Effects

  • Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat.
  • Cardiovascular events: hypertension, thromboembolic complications.
  • Bone mineral density loss: increased risk of osteoporosis with long‑term use.
  • Tumor flare syndrome: temporary worsening of disease symptoms at treatment start.

Precautions & Warnings

Before initiating therapy, several safety considerations are recommended.

  • Pregnancy: avoid use; safety in pregnancy is unknown.
  • Breastfeeding: contraindicated; leuprorelin may be excreted in milk.
  • Cardiovascular disease: assess risk and monitor blood pressure regularly.
  • Bone health: evaluate baseline bone density and consider supplementation.
  • Hormone‑sensitive tumors: monitor disease status closely during treatment.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Leuprorelin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Strong CYP450 inducers (e.g., rifampicin) may lower leuprorelin levels.
  • Concurrent use of long‑acting GnRH antagonists can produce antagonistic hormonal effects.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin) may increase bleeding risk.
  • Bisphosphonates may compound bone density loss.
  • Systemic steroids can mask signs of adrenal insufficiency.
  • Hormonal replacement therapy may counteract leuprorelin’s suppressive action.

Frequently Asked Questions

Leuprone 1-Monatsdepot is a monthly depot injection of leuprorelin, a GnRH agonist used to treat hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids, precocious puberty, and, in some cases, hormone‑sensitive breast cancer.

Leuprorelin initially stimulates pituitary GnRH receptors, causing a brief rise in LH and FSH. Continuous exposure then down‑regulates these receptors, leading to a sustained drop in LH and FSH secretion, which reduces the production of sex hormones (testosterone and estrogen) that drive the targeted diseases.

The specific dose and dosing interval of leuprorelin are determined by the prescribing clinician based on the individual’s condition, disease severity, and treatment goals. The product is supplied as a 1‑month depot formulation for subcutaneous injection.

Safety of leuprorelin in pregnancy and lactation has not been established. It is generally avoided in pregnant women, and breastfeeding is contraindicated because the drug may be excreted in breast milk and affect the infant’s hormonal balance.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and required import documentation.

Leuprorelin is a long‑acting GnRH agonist that provides sustained hormone suppression after an initial flare, similar to goserelin or triptorelin. GnRH antagonists, such as degarelix, block receptors without the flare but require more frequent dosing. Choice depends on clinical context, patient preference, and safety considerations.

Leuprone 1-Monatsdepot should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. The product must be handled in accordance with good distribution practice (GDP) to maintain stability and potency.

Leuprone 1-Monatsdepot is administered as a subcutaneous injection by a qualified healthcare professional. The depot formulation releases leuprorelin slowly over a month, providing continuous hormone suppression without the need for daily dosing.

Serious risks include severe allergic reactions (anaphylaxis), cardiovascular events such as hypertension or thromboembolism, and long‑term bone mineral density loss leading to osteoporosis. Patients should be monitored regularly for these complications.

Leuprorelin should not be used in individuals with known hypersensitivity to the drug, pregnant or breastfeeding women, and patients with uncontrolled cardiovascular disease or severe osteoporosis without appropriate monitoring and management.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Leuprorelin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT